uniQure Entered into a License Agreement with Apic Bio for APB-102 to Treat Amyotrophic Lateral Sclerosis in Patients with SOD1 Mutations
Shots:
- Apic Bio to receive $10M up front & is also eligible to receive ~$45M in milestones upon achievement of regulatory approvals in the US & EU and pre-specified annual net sales along with royalty
- uniQure to get global rights for the development & commercialization of APB-102 & adds to its pipeline of gene therapies for neurological disorders. The IND application for APB-102 has been approved by the US FDA & the therapy also received ODD & FTD. The P-I/II study of APB-102 is expected to be initiated in H2’23
- In preclinical tests using a SOD1-ALS mouse model, APB-102 significantly increased the survival of the affected mice. At suggested clinical doses, relevant SOD1 reduction in spinal cord motor neurons was also shown in rodents & non-human primates
Ref: Globenewswire | Image: uniQure
Related News:- uniQure Receives EMA’s CHMP Positive Opinion of Etranacogene Dezaparvovec for the Treatment of Adults with Hemophilia B
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
